Joel Melnick, Age 61Evanston, IL

Joel Melnick Phones & Addresses

Evanston, IL

Miami Beach, FL

Bannockburn, IL

Chicago, IL

Dallas, TX

Matawan, NJ

Wilmette, IL

Show more

Social networks

Joel Melnick

Linkedin

Education

School / High School: Creighton University 1987

Industries

Pharmaceuticals

Mentions for Joel Melnick

Professional Records

Medicine Doctors

Joel Melnick Photo 1

Dr. Joel Z Melnick - MD (Doctor of Medicine)

Procedures:
Angioplasty
Dialysis
Erythropoietin Test
Hospitals:
408 Brookside Dr, Wilmette, IL 60091
Education:
Medical Schools
Creighton University
Graduated: 1987
Joel Melnick Photo 2

Joel Zachary Melnick, Chicago IL

Specialties:
Internal Medicine
Nephrology
Pediatrics
Pediatric Nephrology
Work:
Pediatric Faculty Foundation
2300 N Childrens Plz, Chicago, IL 60614
Education:
Creighton University (1987)

License Records

Joel Zachary Melnick Md

Licenses:
License #: 18238 - Expired
Category: Medicine
Issued Date: Jul 2, 1990
Effective Date: Oct 2, 1994
Type: Physician

Joel Zachary Melnick Md

Licenses:
License #: 2087 - Expired
Category: Medicine
Issued Date: Jul 1, 1987
Effective Date: Jul 1, 1990
Type: Temporary Educational Permit

Resumes

Resumes

Joel Melnick Photo 3

Joel Melnick

Location:
Greater Chicago Area
Industry:
Pharmaceuticals

Business Records

Name / TitleCompany / ClassificationPhones & Addresses
Joel Zachary Melnick
Medical Doctor
Kleeg LLC 408 Brookside Dr, Wilmette, IL 60091
Joel Zachary Melnick Joel Melnick MD 2300 N Childrens Plz, Chicago, IL 60614
(773) 975-8665

Publications

Us Patents

Use Of Vitamin Ds To Down Regulate The Renin-Angiotensin-Aldosterone System

US Patent:
2005007, Apr 7, 2005
Filed:
Jul 27, 2004
Appl. No.:
10/900418
Inventors:
Joel Melnick - Wilmette IL,
Jin Tian - Waukegan IL,
International Classification:
A61K031/59
A61K009/70
US Classification:
424449000, 514167000
Abstract:
The present invention relates to the use of Vitamin D, preferably paricalcitol, to treat, prevent and delay disease progression of diseases associated with over activation of the renin-angiotensin aldosterone system.

Use Of Vitamin Ds To Treat Kidney Disease

US Patent:
2005012, Jun 9, 2005
Filed:
Oct 27, 2004
Appl. No.:
10/974243
Inventors:
Jin Tian - Waukegan IL,
Joel Melnick - Wilmette IL,
Laura Williams - Gurnee IL,
Leticia Delgado-Herrera - Lake Forest IL,
Ping Qiu - Gurnee IL,
International Classification:
A61K031/59
A61K031/401
A61K009/70
US Classification:
514167000, 424449000, 514423000
Abstract:
Disclosed are compositions containing a VDRA/Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA/Vitamin D analog. Compositions according to the invention include a VDRA/Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.

Use Of Vitamin Ds To Treat Kidney Disease

US Patent:
2005014, Jul 7, 2005
Filed:
Jul 28, 2004
Appl. No.:
10/901660
Inventors:
Jin Tian - Waukegan IL,
Joel Melnick - Wilmette IL,
Laura Williams - Gurnee IL,
Leticia Delgado-Herrera - Lake Forest IL,
International Classification:
A61K031/59
A61K031/401
A61K009/70
US Classification:
514167000, 514423000, 424449000
Abstract:
Disclosed are compositions containing a VDRA/Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA/Vitamin D analog. Compositions according to the invention include a VDRA/Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.

Use Of Vitamin Ds Or Vitamin D Analogs To Treat Cardiovascular Disease

US Patent:
2005019, Sep 1, 2005
Filed:
Jul 29, 2004
Appl. No.:
10/903039
Inventors:
Jin Tian - Waukegan IL,
Joel Melnick - Wilmette IL,
E. Toner - Vernon Hills IL,
Jinshyun Wu-Wong - Libertyville IL,
David Ostrow - Lake Zurich IL,
Laura Williams - Gurnee IL,
Eugene Sun - Libertyville IL,
International Classification:
A61K031/59
A61K009/70
US Classification:
514167000, 424449000
Abstract:
Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to a mammal in need thereof.

Methods Of Using Vitamin D Compounds In The Treatment Of Patients Undergoing Hemodialysis

US Patent:
2005019, Sep 1, 2005
Filed:
Dec 2, 2004
Appl. No.:
11/002014
Inventors:
Joel Melnick - Wilmette IL,
Laura Williams - Gurnee IL,
Michael Amdahl - Wauconda IL,
Jin Tian - Waukegan IL,
Steven Marx - Hoffman Estates IL,
Coleen Hall - Glen Ellyn IL,
Dheerendra Kommala - Gurnee IL,
International Classification:
A61K031/59
US Classification:
514167000
Abstract:
The subject invention relates to methods of using Vitamin D compounds such as, for example, paricalcitol and calcitriol, in the treatment of patients undergoing hemodialysis. More specifically, administration of Vitamin D compounds appears to reduce the incidence of hospitalization, length of days spent in the hospital and morbidity in treated patients.

Use Of Vitamin Ds Or Vitamin D Analogs To Treat Cardiovascular Disease

US Patent:
2005020, Sep 22, 2005
Filed:
Dec 2, 2004
Appl. No.:
11/002934
Inventors:
Jin Tian - Waukegan IL,
Joel Melnick - Wilmette IL,
E. Toner - Vernon Hills IL,
Jinshyun Wu-Wong - Libertyville IL,
David Ostrow - Lake Zurich IL,
Laura Williams - Gurnee IL,
Eugene Sun - Libertyville IL,
Dheerendra Kommala - Gurnee IL,
International Classification:
A61K031/59
A61K031/401
A61K009/70
US Classification:
514167000, 514423000, 424449000
Abstract:
Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to a mammal in need thereof. Additionally disclosed are methods of preventing, inhibiting or treating thrombosis in a mammal in need of such prevention, inhibition or treatment comprising administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to the mammal.

Oral Formulations Of Paricalcitol

US Patent:
2006000, Jan 12, 2006
Filed:
May 25, 2005
Appl. No.:
11/137611
Inventors:
Leticia Delgado-Herrera - Lake Forest IL,
Steve Chamberlin - Waukegan IL,
Dennis Stephens - Mt. Prospect IL,
Joel Melnick - Wilmette IL,
International Classification:
A61K 31/59
US Classification:
514167000
Abstract:
The present invention relates to oral formulations comprising paricalcitol that are available in a variety of different dosage forms that are bioequivalent to one another.

Paricalcitol(Zemplar) Capsule Controls Secondary Hyperparathyroidism (Shpt) In Ckd Stage 5 Patients

US Patent:
2006003, Feb 9, 2006
Filed:
Dec 2, 2004
Appl. No.:
11/002159
Inventors:
Ping Qiu - Gurnee IL,
Joel Melnick - Wilmette IL,
Laura Williams - Gurnee IL,
International Classification:
A61K 31/59
US Classification:
514167000
Abstract:
Oral paricalcitol for sustained reduction of parathyroid hormone in dialysis patients.

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.